首页|期刊导航|Pharmacoeconomics and Policy|Current clinical practice including treatment patterns and pathways in idiopathic pulmonary fibrosis patients in China:A real-world analysis

Current clinical practice including treatment patterns and pathways in idiopathic pulmonary fibrosis patients in China:A real-world analysis

Han Bao Yifei Jian Cristina Penaloza‑Ramos Madhu Kanakapura Zhongyi Deng Jianwei Xuan Hui Zhao

Pharmacoeconomics and Policy2026，Vol.2Issue(1)：P.27-37,11.

Pharmacoeconomics and Policy2026，Vol.2Issue(1)：P.27-37,11.DOI:10.1016/j.pharp.2026.03.005

Current clinical practice including treatment patterns and pathways in idiopathic pulmonary fibrosis patients in China:A real-world analysis

Han Bao ¹Yifei Jian ¹Cristina Penaloza‑Ramos ²Madhu Kanakapura ²Zhongyi Deng ³Jianwei Xuan ¹Hui Zhao⁴

作者信息

1. Institute of Pharmaceutical Economics,School of Pharmacy,Sun Yat‑sen University,Guangzhou 510006,China
2. Boehringer Ingelheim International GmbH,Ingelheim am Rhein 55216,Germany
3. Boehringer Ingelheim International GmbH,Ingelheim am Rhein 55216,Germany Institute for Medical Information Processing,Biometry,and Epidemiology(IBE),Ludwig‑Maximilians‑University Munich,Munich 81377,Germany
4. Department of Pulmonary and Critical Care Medicine,The Second Hospital of Shanxi Medical University,Taiyuan 030001,China
折叠

摘要

关键词

Idiopathic pulmonary fibrosis/Treatment patterns/Clinical pathways/Real‑world evidence/Nintedanib

分类

医药卫生

引用本文复制引用

Han Bao,Yifei Jian,Cristina Penaloza‑Ramos,Madhu Kanakapura,Zhongyi Deng,Jianwei Xuan,Hui Zhao..Current clinical practice including treatment patterns and pathways in idiopathic pulmonary fibrosis patients in China:A real-world analysis[J].Pharmacoeconomics and Policy,2026,2(1):P.27-37,11.

基金项目

funded by Boehringer Ingelheim International GmbH,Germany(Grant No.:ONIS 1305-O118). （Grant No.:ONIS 1305-O118）

Pharmacoeconomics and Policy

ISSN：2950-2667

访问量0

下载量0

段落导航